Astec Lifesciences Ltd

Astec Lifesciences Results Update

Astec LifeSciences released a press release on its Q2 and H1 FY27 results, approved October 26, 2026. Q2 FY27 losses widened year on year.

Astec Lifesciences Other Announcement

Astec LifeSciences filed a Reg 54 Nil Security Cover certificate for its listed unsecured NCDs, stating the security cover format is not applicable. This is routine compliance paperwork with no new money or business event.

Astec Lifesciences Q2 FY27 Results: Net Loss of ₹37.4 Cr, Loss Widens

Astec Lifesciences Ltd reported revenue from operations of ₹72 Cr (-2.3% YoY) and a net loss of ₹37.4 Cr for Q2 FY27.

Key figure

Net loss ₹37.4 Cr

Astec Lifesciences Board Meeting Date

Astec LifeSciences will hold a board meeting on October 26, 2026, to consider and approve standalone and consolidated unaudited financial results for the half-year ending September 2026.

Astec Lifesciences Other Announcement

Astec Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.

Astec Lifesciences Debt & Borrowing: ₹25 Cr

Astec LifeSciences Limited has redeemed Commercial Papers amounting to ₹25 Crore. The payment was made on the maturity date, 13th October, 2026.

Value

₹25.00 Cr

Astec Lifesciences Other Announcement

Astec Lifesciences filed a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026, confirming no rematerialization requests received.

Astec Lifesciences Debt & Borrowing: ₹75 Cr

Astec LifeSciences fixed record dates for redemption of three CP series totaling Rs.75 Crore maturing Nov–Dec 2026. All three CPs are listed on the NSE debt segment.

Value

₹75.00 Cr

Astec Lifesciences Price Movement Clarification

Astec LifeSciences Limited clarified there are no undisclosed material developments explaining the recent significant increase in share trading volume. The company confirmed full compliance with SEBI listing regulations.

Astec Lifesciences Price Movement Clarification

Astec LifeSciences responded to an NSE surveillance query on volume spurt. The company confirmed no developments requiring mandatory disclosure under LODR or PIT Regulations.

Astec Lifesciences Debt & Borrowing: ₹25 Cr

Astec LifeSciences Limited has confirmed the timely payment of the maturity amount for its commercial paper. The redemption amount totals ₹25 Crore.

Value

₹25.00 Cr